The DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index.
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
Open accessAbstract
SUMMARY While mutations affecting protein-coding regions have been examined across many cancers, structural variants at the genome-wide level are still poorly defined. Through integrative deep whole genome and transcriptome analysis of 101 castration-resistant prostate cancer metastases (109X tumor / 38X normal coverage), we identified structural variants altering critical regulators of tumorigenesis and progression not detectable by exome approaches. Notably, we observed amplification of an intergenic enhancer region 624 kilobases upstream of the androgen receptor (AR) in 81% of patients, correlating with increased AR expression. Tandem duplication hotspots also occur near MYC, in lncRNAs associated with post-translational MYC regulation. Classes of structural variations were linked to distinct DNA repair deficiencies, suggesting their etiology, including associations of CDK12 mutation with tandem duplications, TP53 inactivation with inverted rearrangements and chromothripsis, and BRCA2 inactivation with deletions. Together, these observations provide a comprehensive view of how structural variations affect critical regulators in metastatic prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most PCas express AR throughout the course of the disease2–5”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The androgen receptor (AR) is a critical driver of prostate cancer (PCa).”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We and other groups have identified tumor alterations that reactivate AR signaling during treatment with an ARSI2,22–29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These mechanisms of resistance include AR gene amplification22,23, AR enhancer amplification2,24,25, AR mutation26, AR genomic structural rearrangements27, AR splice variants28 and polymorphisms in androgen metabolism genes29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, deep deletions (primarily of BRCA2; Supplementary Fig. 23) occurred much more frequently in prostate cancer (33%) compared to other cancer types, consistent with previous observations28.”
From Pan-cancer landscape of homologous recombination deficiency. (2020) · cites this paper as [28]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,893
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,632 · cited 1×
“While over 160,000 American men are diagnosed with prostate cancer each year, <20% of patients will experience progression to the lethal form of the disease, termed metastatic castration-resistant prostate cancer (mCRPC) (Siegel et al., 2018).”
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,724 · cited 2×
“2.0 Zhang et al., 2013 https://cran.r-project.org/web/packages/RCircos/index.html ANNOVAR v2018Apr16 Wang et al., 2010 http://annovar.openbioinformatics.org/en/latest/ Cell 174, 1–12.e1–e3, July 26, 2018 e1 Please cite this article in press as: Quigley et al., Genomic Hallmarks and Structural…”
InfluentialCingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Ohno, S. (1970) · doi:10.1007/978-3-642-86659-3 · Cited by 7,833
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,965
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846 · cited 3×
“We observed mutually exclusive fusions activating the ETS family members ERG, ETV1, ETV4, and ETV5 in 59% of our cohort (Figure 1C; fusions listed in Table S3).”
InfluentialSelf-citation
Flagged first, then by citations
1 of the 73 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 501–600 of 738
ANP32B inhibition suppresses the growth of prostate cancer cells by regulating c-Myc signaling
Zhou, C., Ma, H., Yu, W., Zhou, Y., Zhang, X., Meng, Y., Chen, C., Zhang, J., & Shi, G. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.149543 · Cited by 5
Self-citationHuang, F., Li, K., Chen, Z., Cui, Z., Hankey, W., Fang, K., Yan, J., Wang, H., Jin, V. X., Dong, Y., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03239-2 · Cited by 5
Dutta, S., Khedmatgozar, H., Patel, G. K., Latour, D., Welsh, J., Mustafi, M., Mitrofanova, A., Tripathi, M., & Nandana, S. (2024) · Oncogene · doi:10.1038/s41388-024-03252-5 · Cited by 6
Price, M. J., Vashistha, V., Winski, D., Kelley, M. J., Bitting, R. L., & Montgomery, B. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00461 · Cited by 5
Molecular predictors of metastasis in patients with prostate cancer
Lin, J., Zhuo, Y., Zhang, Y., Liu, R., & Zhong, W. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2187289 · Cited by 5
Habault, J., Schneider, J. A., Ha, S., Ruoff, R., Pereira, L. D., Puccini, J., Ranieri, M., Ayasun, R., Deng, J., Kasper, A. C., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0196 · Cited by 5
Self-citationAl‐Toubat, M., Serrano, S., Elshafei, A., Koul, K., Feibus, A. H., & Balaji, K. C. (2023) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2023.09.014 · Cited by 5
Su, M., Lee, A. M., Zhang, W., Maeser, D., Gruener, R. F., Deng, Y., & Huang, R. S. (2024) · Pharmaceuticals · doi:10.3390/ph17050569 · Cited by 5
Integrative identification of non-coding regulatory regions driving metastatic prostate cancer
Woo, B. J., Moussavi-Baygi, R., Karner, H. M., Karimzadeh, M., Yousefi, H., Lee, S. M., Garcia, K., Joshi, T. V., Yin, K., Navickas, A., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114764 · Cited by 5
“21 Model robustness with respect to epigenetic features—”
InfluentialSelf-citationMa, C., Shi, X., Li, X., Zhang, Y.-P., & Peng, M. (2024) · BMC Genomics · doi:10.1186/s12864-024-10875-1 · Cited by 5
Adverse prognosis gene expression patterns in metastatic castration‐resistant prostate cancer
Sharifi, M. N., Feng, E. L.-L., Rydzewski, N. R., Taylor, A. K., Sperger, J. M., Shi, Y., Helzer, K. T., Bootsma, M. L., Carreno, V., Chang, A. H., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70001 · Cited by 5
Self-citationCirculating Tumour DNA as a Biomarker Source in Metastatic Prostate Cancer
Wyatt, A. W., & Vandekerkhove, G. R. (2020) · Société Internationale d’Urologie Journal · doi:10.48083/vsoo5322 · Cited by 5
Self-citationTriple-arm androgen blockade for advanced prostate cancer: a review
Desai, M. H., Parsi, M., & Potdar, R. R. (2021) · Medical Oncology · doi:10.1007/s12032-021-01520-y · Cited by 5
Velasco, M. A. D., Kura, Y., Ando, N., Sako, N., Banno, E., Fujita, K., Nozawa, M., Yoshimura, K., Sakai, K., Yoshikawa, K., et al. (2021) · Cancers · doi:10.3390/cancers13163975 · Cited by 5
Bright, J. R., Lis, R. T., Ku, A. T., Terrigino, N. T., Whitlock, N. C., Trostel, S. Y., Carrabba, N. V., Harmon, S. A., Türkbey, B., Wilkinson, S. C., et al. (2022) · The Journal of Urology · doi:10.1097/ju.0000000000002492 · Cited by 5
Mutator-Derived lncRNA Landscape: A Novel Insight Into the Genomic Instability of Prostate Cancer
Tang, L., Li, W., Xu, H., Zheng, X. S., Qiu, S., He, W., Wei, Q., Ai, J., Yang, L., & Liu, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.876531 · Cited by 4
SWI/SNF chromatin remodelers in prostate cancer progression
Ordonez‐Rubiano, S. C., Strohmier, B. P., Sood, S., & Dykhuizen, E. C. (2024) · Frontiers in Epigenetics and Epigenomics · doi:10.3389/freae.2023.1337345 · Cited by 5
Utility and Clinical Application of Circulating Tumor DNA (ctDNA) in Advanced Prostate Cancer
Kostos, L. K., Fettke, H., Kwan, E. M., & Azad, A. (2023) · Société Internationale d’Urologie Journal · doi:10.48083/rfsh8912 · Cited by 5
Bjerknes, C., Framroze, B., Currie, C., Pettersen, C. H. H., Axcrona, K., & Hermansen, E. (2022) · Marine Drugs · doi:10.3390/md20040228 · Cited by 5
“Androgen resistance is partly caused by amplification and mutations of the androgen receptor that increase the activity of the androgen receptor (AR) pathway [7].”
Macrini, S., Francesconi, S., Caprera, C., Lancia, D., Corsi, M., Gunnellini, M., Rocchi, A., Pireddu, A., Marziani, F., Mosillo, C., et al. (2022) · Cancers · doi:10.3390/cancers14061542 · Cited by 5
Revealing the impact of recurrent and rare structural variants in multiple myelomaPreprint
Rustad, E. H., Yellapantula, V. D., Głodzik, D., Maclachlan, K. H., Diamond, B. T., Boyle, E. M., Ashby, C., Blaney, P., Gundem, G., Hultcrantz, M. L., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2019.12.18.881086 · Cited by 5
A Pan-Cancer Census of Dominant Tumor Immune ArchetypesPreprint
Combes, A. J., Samad, B., Tsui, J., Chew, N. W., Yan, P., Reeder, G. C., Kushnoor, D., Shen, A., Davidson, B., Barczac, A. J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.26.441344 · Cited by 5
Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer
Virtanen, T., Kwan, E. M., Parekh, K., Bacon, J. V. W., Huang, C.-C. F., Yu, I. P. L., Ryyppö, L., Bernales, C. Q., Donnellan, G., Tam, C. S. L., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.10.1236 · Cited by 5
Self-citationMolecular subtypes of metastatic prostate cancer: from pathophysiology to diagnosis
Dsouza, J. M., Sayar, E., Schweizer, M. T., Harmon, S. A., Morrissey, C. M., Beltran, H., Nelson, P. S., Liang Cheng, C., Ding, C. C., & Haffner, M. C. (2025) · Histopathology · doi:10.1111/his.70033 · Cited by 4
López, J. C. V., Yu, C., Knutson, T. P., Kobilka, A., Lyman, J. A., Guo, S., Luo, B., Munro, S. A., LI, Y., Heer, R., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2779 · Cited by 4
Self-citationMolecular pathology of rare histologic variants and treatment-resistant lineages of prostate cancer
Watanabe, R., Miura, N., Kikugawa, T., Saika, T., Haffner, M. C., & Nelson, P. S. (2026) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2025.110987 · Cited by 4
Guo, J., Wei, Z., Jia, T., Wang, L., Nama, N., Liang, J., Liao, X., Liu, X., Gao, Y., Liu, X., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04429-4 · Cited by 4
Androgen receptor post-translational modifications and their implications for pathology
Montoya-Novoa, I., Gardeazábal-Torbado, J. L., Alegre‐Martí, A., Fuentes‐Prior, P., & Estébanez‐Perpiñá, E. (2024) · Biochemical Society Transactions · doi:10.1042/bst20231082 · Cited by 4
Ma, F., Chen, S., Cecchi, L. G., Ersoy-Fazlioglu, B., Russo, J. W., Arai, S., Awad, S., Calagua, C., Xie, F., Poluben, L., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci192368 · Cited by 4
Gulliver, C., Huss, S., Semjonow, A., Baillie, G. S., & Hoffmann, R. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02417-5 · Cited by 4
Compromised CDK12 activity causes dependency on the high activity of O-GlcNAc transferase
Pallasaho, S., Gondane, A., Kutz, J., Liang, J., Yalala, S., Duveau, D. Y., Pospiech, H., Thomas, C. J., Loda, M. F., & Itkonen, H. M. (2024) · Glycobiology · doi:10.1093/glycob/cwae081 · Cited by 4
Rollin, S., Lawrence, M. G., Joshua, A. M., & Selth, L. A. (2024) · Endocrine Related Cancer · doi:10.1530/erc-24-0208 · Cited by 4
Ma, H., Zhou, C., Ge, J., Yu, W., Zhou, Y., Wang, P., Zhang, X., Zhang, J., & Shi, G. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2022.1110723 · Cited by 4
Self-citationSchimmelpfennig, C., Rade, M., Fuessel, S., Löffler, D., Blumert, C., Bertram, C., Borkowetz, A., Otto, D. J., Puppel, S.-H., Hönscheid, P., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11019-6 · Cited by 4
Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancers
Boruah, N., Hoyos, D., Moses, R., Hausler, R. M., Desai, H., Le, A. D., Good, M., Kelly, G., Raghavakaimal, A., Tayeb, M. N., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73163-4 · Cited by 4
Toivanen, R., Porter, L. H., Li, Z., Clouston, D. R., Risbridger, G. P., & Taylor, R. A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.020 · Cited by 4
The new approaches to the treatment of castration- resistant prostate cancer: PARP inhibitors
Грицкевич, А. А., Русаков, И. Г., Baitman, T. P., & Владимирович, М. С. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-4s-44-50 · Cited by 4
Evolution of the prostate cancer genome towards resistance
Lorenzin, F., & Demichelis, F. (2019) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2019.01 · Cited by 4
van Dessel, L. F., van Riet, J., Smits, M., Zhu, Y., Hamberg, P., van der Heijden, M. S., Bergman, A. M., van Oort, I. M., de Wit, R., Voest, E. E., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/546051 · Cited by 4
Predictive Biomarkers in Prostate Cancer: Is It Time To Go “All In” on Liquid Biopsies?
Kanayama, M., & Luo, J. (2020) · European Urology · doi:10.1016/j.eururo.2020.04.053 · Cited by 4
Hawley, J. R., Zhou, S., Arlidge, C., Grillo, G., Kron, K., Hugh-White, R., van der Kwast, T., Fraser, M. E., Boutros, P. C., Bristow, R. G., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.05.425333 · Cited by 4
Wilkinson, S. C., Ku, A. T., Lis, R. T., King, I. M., Low, D., Trostel, S. Y., Bright, J. R., Terrigino, N. T., Baj, A., Fenimore, J. M., et al. (2024) · medRxiv · doi:10.1101/2024.02.09.24302395 · Cited by 4
Frank, S. B., Persse, T. W., Coleman, I., Bankhead, A., Li, D., Sarkar, N. D., Wilson, D., Rudoy, D., Vashisth, M., Galipeau, P., et al. (2024) · eLife · doi:10.7554/elife.100081 · Cited by 4
Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance
Gao, S., Patten, N. D., & Cai, C. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.05.003 · Cited by 4
Biological Knowledge Graph-Enhanced Cancer State Prediction Network with Adjustable Connections
Liu, Y., Yi, S., Chen, X., Guo, W., & He, L. (2025) · Big Data Mining and Analytics · doi:10.26599/bdma.2025.9020006 · Cited by 3
Shore, N. D., Fizazi, K. S., Schweizer, M. T., Castro, E., Azad, A. A., George, D. J., da Trindade, K. M., Zeng, H., Shrivastava, N., Tonkovyd, S., et al. (2026) · Future Oncology · doi:10.1080/14796694.2026.2667441 · Cited by 3
Zeng, J., Chen, J.-H., Li, M., Zhong, C., Liu, Z., Wang, Y., Li, Y., Jiang, F., Fang, S., & Zhong, W. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1191129 · Cited by 3
Dincman, T. A., Karam, J. A. Q., Giordano, A., Li, H., Drusbosky, L. M., Gourdin, T. S., Howe, P. H., & Lilly, M. B. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1202277 · Cited by 3
Self-citationWu, X., Luo, X., Li, C.-C., Zhao, X., Zhang, C., Chen, X., Lu, Z.-F., Wu, T., Yu, H.-N., Peng, C., et al. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01274-z · Cited by 3
Zhang, W., Lee, A. M., Lee, L., Dehm, S. M., & Huang, R. S. (2024) · Clinical and Translational Science · doi:10.1111/cts.70030 · Cited by 3
Self-citationLiu, S. (2024) · American Journal of Clinical and Experimental Urology · doi:10.62347/jnbr1463 · Cited by 4
Analysis of homologous recombination deficiency in prostate cancer
Iyevleva, A. G., Алексахина, С. Н., Соколенко, А. П., Отраднова, Е. А., Никитина, А. С., Кашко, К. А., Syomina, M. V., Morozova, N. S., Шестакова, А. Д., Kuligina, E. S., et al. (2025) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2025-24-1-59-69 · Cited by 4
Zhang, J., Pan, J., Lin, J., Cai, Y., Liu, Y., Lin, F., Guan, H., Zhou, G., Wei, D., Wang, Z., et al. (2025) · Cancer Science · doi:10.1111/cas.70149 · Cited by 3
Self-citationThe role of CDK12 in tumor biology
Dzimková, M., Procházková, J., Klát, J., & Kohoutek, J. (2020) · Klinicka onkologie · doi:10.14735/amko2020260 · Cited by 3
Miyahira, A. K., Hawley, J. E., Adelaiye-Ogala, R. M., Calais, J., Nappi, L., Parikh, R. B., Seibert, T. M., Wasmuth, E. V., Wei, X. X., Pienta, K. J., et al. (2022) · The Prostate · doi:10.1002/pros.24461 · Cited by 4
Zhang, W., & Huang, R. S. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2365370 · Cited by 3
Zhang, S., Zhao, J., Zhang, H., Fu, D., Qiao, L., Wu, B., Li, X., Hao, Y., Zheng, X., Liang, Z., et al. (2024) · Journal of Integrative Agriculture · doi:10.1016/j.jia.2024.07.047 · Cited by 3
Gesztes, W., Lap, C. J. G., Rajendran, R., Dalivand, M. M., Diao, G., Liu, S., Jain, M. M., & Nava, V. E. (2025) · Cancers · doi:10.3390/cancers17061004 · Cited by 3
Olaparib for the Treatment of Metastatic Prostate Cancer
Maurice‐Dror, C., Wyatt, A. W., & Chi, K. N. (2021) · Future Oncology · doi:10.2217/fon-2020-1245 · Cited by 4
Self-citationXi, J., Deng, Z., Liu, Y., Wang, Q., & Shi, W. (2023) · PeerJ · doi:10.7717/peerj.14843 · Cited by 3
“Since the most relevant basis of cancer drivers is DNA aberrations in cancer samples, the existing computational driver detection approaches mainly focus on DNA sequencing data, and utilize the information of aberrations like single nucleotide variations [9, 10, 11], copy number alternations [12, 13], and structural v…”
Imagerie du cancer de la prostate oligométastatique, le point de vue du médecin nucléaire
Talbot, J., Aveline, C., Zhang-Yin, J. T., Nataf, V., Rusu, T., Balogová, S., Gauthé, M., & Montravers, F. (2019) · Médecine Nucléaire · doi:10.1016/j.mednuc.2019.01.036 · Cited by 3
Improving personalized prediction of cancer prognoses with clonal evolution modelsPreprint
Tao, Y., Rajaraman, A., Cui, X., Cui, Z., Eaton, J., Kim, H., Ma, J., & Schwartz, R. S. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/761510 · Cited by 3
CDK12 Mutation in Advanced Prostate Cancer: A Marker for Clinical Subtype?
Wang, X., Chen, H., Luo, J., & Xie, L. (2019) · European Urology · doi:10.1016/j.eururo.2019.10.015 · Cited by 3
Alqaisi, H. A., Al-Ezzi, E. M., & Hansen, A. R. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.78 · Cited by 2
Why ARNT Prostate Tumors Responding to Enzalutamide?
Zhang, M., Moreno-Rodriguez, T., & Quigley, D. A. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0702 · Cited by 3
Self-citationLarge tandem duplications in cancer result from transcription and DNA replication collisionsPreprint
Yang, Y., Badura, M. L., O’Leary, P. C., Delavan, H. M., Robinson, T. M., Egusa, E. A., Zhong, X., Swinderman, J. T., Li, H., Zhang, M., et al. (2023) · medRxiv · doi:10.1101/2023.05.17.23290140 · Cited by 3
Self-citationLingadahalli, S., Ersoy-Fazlioglu, B., Altıntaş, U. B., Cingöz, A., Tekoglu, E., Yu, I. P. L., Dikbas, U. M., Andomat, H., Kulaç, İ., Morova, T., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.04.556101 · Cited by 3
Self-citationZakari, S. (2023) · Preprints.org · doi:10.20944/preprints202310.0345.v1 · Cited by 3
Nationwide Genomic Data Analysis of Japanese Prostate Cancer Patients From C‐ CAT Database
Tsukahara, S., Shiota, M., Nagakawa, S., Tanegashima, T., Kobayashi, S., Matsumoto, T., & Eto, M. (2025) · Cancer Medicine · doi:10.1002/cam4.71085 · Cited by 2
How structural variation shapes the cancer epigenome
MacLennan, S., & Marra, M. A. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.09.001 · Cited by 2
Ren, Y.-Z., Zhao, M.-N., Du, F.-L., Wu, L., Wang, L., & Lou, J.-T. (2026) · Oncogene · doi:10.1038/s41388-026-03687-y · Cited by 2
Xu, Z., Lv, W., Hu, X., Li, Y., Peng, X., He, C., Lin, L., Lan, L., Sui, X., Liu, X., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106182 · Cited by 2
“Future work using lineage tracing, as well as in vitro and in vivo models, will be essential to validate the causal roles of these SSVs in promoting invasiveness and shaping the tumour microenvironment.”
Chen, Y., He, K., Qu, W., Ma, L., Su, X., Liu, X., Kang, Z., Li, F., Yan, J., Wang, Z., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116667 · Cited by 2
Duong, Q. H., Le, T. K., Tran, T. T., Audebert, S., Camoin, L., Nguyen, N. G., Baboudjian, M., Giusiano, S., Phan, U. T. T., Zaghdoudi, S., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03695-6 · Cited by 2
“The samples in this study were collected from men with metastatic castration-resistant prostate cancer (mCRPC) [21].”
Self-citationEvaluation of novel treatments for metastatic castration-resistant prostate cancer
Güner, G., & Arslan, Ç. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2652456 · Cited by 2
“Alterations in the PTEN/PI3K/AKT pathway occur in 30–40% of mCRPC and are associated with resistance to AR-targeted therapies [23].”
Molecular Pathology of Prostate Cancer
Chen, J., Nelson, W. G., Sfanos, K. S., Yegnasubramanian, S., & Marzo, A. M. D. (2023) · Springer eBooks · doi:10.1007/978-3-031-35118-1_14 · Cited by 2
Epigenetic (De)regulation in Prostate Cancer
Xu, C., Zhao, S., & Cai, L. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-45654-1_10 · Cited by 3
Self-citationA platform-independent AI tumor lineage and site (ATLAS) classifier
Rydzewski, N. R., Shi, Y., Li, C., Chrostek, M. R., Bakhtiar, H., Helzer, K. T., Bootsma, M. L., Berg, T. J., Harari, P. M., Floberg, J. M., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-05981-5 · Cited by 2
Self-citationPanebianco, M., Cereda, V., & D'Andrea, M. R. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00260 · Cited by 3
Androgen Receptor Promotes Lung Cancer Metastasis by Modifying the miR23a-3p/EPHB2 Pathway
Yang, Y., Huang, J., & Yu, W.-W. (2024) · Current Medical Science · doi:10.1007/s11596-024-2891-1 · Cited by 2
Self-citationCRISPR/Cas9 Technology Providing the Therapeutic Landscape of Metastatic Prostate Cancer
Park, J., & Kim, J. (2024) · Pharmaceuticals · doi:10.3390/ph17121589 · Cited by 2
Mutational landscape of cancer and how latest technologies can help in simplifying the understanding
Deshmukh, S. S., Manoharan, A., Sabih, A. N., Dullea, A. D., & Mohammadi, S. M. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15504-8.00005-3 · Cited by 2
The Landscape of Prostate Tumor Methylation
Arbet, J., Yamaguchi, T. N., Shiah, Y.-J., Hugh-White, R., Wiggins, A., Oh, J., Zeltser, N., Gebo, T., Foucal, A., Lesurf, R., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0761 · Cited by 2
Machado, R. S., Tristão, D. C., Araújo, N. M., Seif, E. J. M., da Cruz, K. A. S., Morale, M. G., Rubio, I. G. S., Lago, J. H. G., & Tamura, R. E. (2025) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2025.100257 · Cited by 2
Genomic and transcriptomic sequencing in prostate cancer
Rifai, S., Rifai, A., Shi, X., Khan, M. A., Guang, W., Wang, L., Tallon, L. J., & Hussain, A. (2025) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001136 · Cited by 2
Latest progress in molecular biology and treatment in genitourinary tumours
del Alba, A. G., Arranz, J. Á., Joaquim Bellmunt, B., Maroto, P., Calvo, O. F., Valderrama, B. P., González‐Billalabeitia, E., Méndez-Vidal, M. J., Cassinello, J., Romero-Laorden, N., et al. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02373-z · Cited by 2
Wang, S., Ekoue, D. N., Raj, G. V., & Kittler, R. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.09.010 · Cited by 2
Clinical Evaluation of Non-invasive Nanodiagnostics for PCa Risk Stratification
Koo, K. M. (2019) · Springer theses · doi:10.1007/978-3-030-31000-4_6 · Cited by 2
Identification of Metabolism-Related Gene-Based Subgroup in Prostate Cancer
Yu, G., Liang, B., Yin, K., Zhan, M., Gu, X., Wang, J., Song, S., Liu, Y., Yang, Q., Ji, T., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.909066 · Cited by 2
“Some long non-coding RNAs, such as CCAT1 (52, 53), PVT1 (54), PRNCR1 (55), and PCAT1 (56), in 8q24.”
Miyahira, A. K., Kamran, S. C., Jamaspishvili, T., Marshall, C. H., Maxwell, K. N., Parolia, A., Zorko, N. A., Pienta, K. J., & Soule, H. R. (2024) · The Prostate · doi:10.1002/pros.24721 · Cited by 2
Self-citationNon-epigenetic induction of HEXIM1 by DNMT1 inhibitors and functional relevance
Sharma, V., & Montano, M. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-78058-y · Cited by 2
Correcting reference bias from the Illumina Isaac aligner enables analysis of cancer genomesPreprint
Cornish, A. J., Chubb, D., Frangou, A., Hoang, P. H., Kaiser, M., Wedge, D. C., & Houlston, R. S. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/836171 · Cited by 2
One of These Things is Not Like the Others: Targeting ATM-mutant Prostate Cancer
Quigley, D. A. (2020) · European Urology · doi:10.1016/j.eururo.2020.11.018 · Cited by 2
Self-citationCapped nascent RNA sequencing reveals novel therapy-responsive enhancers in prostate cancerPreprint
Cotter, K. A., Shah, S. R., Paramo, M. I., Lou, S., Li, Y., Rubin, P. D., Chen, Y., Gerstein, M., Rubin, M. A., & Yu, H. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.08.487666 · Cited by 2
Mining Thousands of Genomes to Classify Somatic and Pathogenic Structural VariantsPreprint
Layer, R. M., Sedlazeck, F. J., Pedersen, B. S., & Quinlan, A. R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.21.440844 · Cited by 2
Hawley, J. E., Obradović, A., Dallos, M. C., Lim, E. A., Runcie, K. D., Ager, C. R., McKiernan, J., Anderson, C. B., DeCastro, J., Weintraub, J. L., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.06.490968 · Cited by 2
Anselmino, N., Labanca, E., Song, X., Yang, J., Shepherd, P. D. A., Dong, J., Kundra, R., Schultz, N., Zhang, J., Araujo, J. C., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.21.500652 · Cited by 2
Self-citationZhang, S., Kumar, K. H., Shapira, O., Yao, X., Wala, J. A., Dubois, F. P. B., Gold, R. M., Haber, J. E., Cherniack, A. D., Imielinski, M. B., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.13.561748 · Cited by 2
Canonical AREs are tumor suppressive regulatory elements in the prostatePreprint
Augello, M. A., Chen, X., Liu, D., Lin, K., Hakansson, A., Sjöström, M., Khani, F., Deonarine, L. D., Liu, Y., Travascio-Green, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.23.581466 · Cited by 2
Self-citationFan, Z., Yu, Q., Deng, J., Wang, X., Yu, H., Fan, X., & Xie, J. (2024) · Environmental Toxicology · doi:10.1002/tox.24118 · Cited by 1
Metadata
- Authors
- Quigley, D. A., Dang, H. X., Zhao, S. G., Lloyd, P., Aggarwal, R., Alumkal, J. J., Foye, A., Kothari, V., Perry, M. D., Bailey, A. M., Playdle, D., Barnard, T. J., Zhang, L., Zhang, J., Youngren, J. F., Cieslik, M. P., Parolia, A., Beer, T. M., Thomas, G., Chi, K. N., Gleave, M., Lack, N. A., Zoubeidi, A., Reiter, R. E., Rettig, M. B., Witte, O., Ryan, C. J., Fong, L., Kim, W., Friedlander, T., Chou, J., Li, H., Das, R., Li, H., Moussavi-Baygi, R., Goodarzi, H., Gilbert, L. A., Lara, P. N., Evans, C. P., Goldstein, T. C., Stuart, J. M., Tomlins, S. A., Spratt, D. E., Cheetham, R. K., Cheng, D. T., Farh, K., Gehring, J. S., Hakenberg, J., Liao, A., Febbo, P. G., Shon, J., Sickler, B., Batzoglou, S., Knudsen, K. E., He, H. H., Huang, J., Wyatt, A. W., Dehm, S. M., Ashworth, A., Chinnaiyan, A. M., Maher, C. A., Small, E. J., & Feng, F. Y.
- Affiliations
- University of California, San Francisco (US)
- Washington University in St. Louis (US)
- University of Michigan (US)
- Oregon Health & Science University (US)
- BC Cancer Agency (CA)
- University of British Columbia (CA)
- University of California, Los Angeles (US)
- University of Minnesota (US)
- University of California Davis Medical Center (US)
- University of California, Santa Cruz (US)
- Illumina (United States) (US)
- Thomas Jefferson University (US)
- University Health Network (CA)
- Duke University (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Chinnaiyan, Arul M.
- Maher, Christopher A.
- Small, Eric J.
- Feng, Felix Y.
- ORCID
- Quigley, David A.
- Dang, Ha X.
- Zhao, Shuang G.
- Lloyd, Paul
- Aggarwal, Rahul
- Alumkal, Joshi J.
- Foye, Adam
- Kothari, Vishal
- Perry, Marc D.
- Zhang, Li
- Zhang, Jin
- Youngren, Jack F.
- Cieslik, Marcin P.
- Parolia, Abhijit
- Beer, Tomasz M.
- Thomas, George
- Chi, Kim N.
- Gleave, Martin
- Lack, Nathan A.
- Zoubeidi, Amina
- Reiter, Robert E.
- Rettig, Matthew B.
- Witte, Owen
- Ryan, Charles J.
- Fong, Lawrence
- Kim, Won
- Friedlander, Terence
- Chou, Jonathan
- Li, Haolong
- Das, Rajdeep
- Li, Hui
- Goodarzi, Hani
- Gilbert, Luke A.
- Lara, Primo N.
- Evans, Christopher P.
- Goldstein, Theodore C.
- Stuart, Joshua M.
- Tomlins, Scott A.
- Spratt, Daniel E.
- Farh, Kyle
- Gehring, Julian S.
- Hakenberg, Jörg
- Shon, John
- Sickler, Brad
- Batzoglou, Serafim
- Knudsen, Karen E.
- He, Housheng H.
- Huang, Jiaoti
- Wyatt, Alexander W.
- Dehm, Scott M.
- Ashworth, Alan
- Chinnaiyan, Arul M.
- Maher, Christopher A.
- Small, Eric J.
- Feng, Felix Y.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 174
- Issue
- 3
- Pages
- 758-769.e9
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC6425931
- OpenAlex
- W2884001931
- Semantic Scholar
- c72ffe522bd85597687b47e4d3db90ec72b4fc80
- Cited by
- 733
- References
- 73
- Citations by year
- 2026: 48 · 2025: 73 · 2024: 102 · 2023: 107 · 2022: 94 · 2021: 110 · 2020: 102 · 2019: 81 · 2018: 15
- FWCI
- 58.02
- Type
- journal article
- Language
- en
- Update notices
- erratum (2018-10-18)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Stand Up To Cancer-Prostate Cancer Foundation Prostate Cancer Dream Team Award (SU2C-AACR-DT0812, SU2C-AACR-DT0712)
- Movember Foundation
- Goldberg-Benioff Research Fund for Prostate Cancer Translational Biology
- Prostate Cancer Foundation Challenge
- V Foundation
- BRCA Foundation Young Investigator Award
- Department of Defense (W81XWH-16-1-0747, W81XWH-15-1-0562, PC160429, W81XWH-17-1-0192)
- Early Detection Research Network (U01 CA214170)
- Prostate SPORE (P50 CA186786, P50 CA097186)
- NIH (R01CA174777)
- NCI T32 (CA108462)
- Prostate Cancer Foundation Young Investigator Awards
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- castration-resistant prostate cancer, metastatic prostate cancer, structural variants, androgen receptor, c-Myc, tandem duplication, long non-coding RNA, DNA repair deficiency, CDK12, TP53, chromothripsis, BRCA2
- MeSH terms
- Whole Genome Sequencing, Aged, Aged, 80 and over, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Prostatic Neoplasms, Receptors, Androgen, Tumor Suppressor Protein p53, Proto-Oncogene Proteins c-myc, Cyclin-Dependent Kinases, Tandem Repeat Sequences, Gene Expression Profiling, Genomics, BRCA2 Protein, Genomic Structural Variation, DNA Copy Number Variations, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
